Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP & CCO | August 01, 2012 | August 01, 2012 |
| EXELON CORPEXC · Entity 3050 | Director | April 28, 2026 | April 29, 2026 |
| ILLUMINA, INC.ILMN · Entity 3137 | Director | May 21, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date August 01, 2012 · Filed August 01, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,992 |
Reported balance
After 2012-08-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2012-08-01 · Exercise / conversion · Acquired 5,125 · Balance 41,992 |
| Common StockSEC Table I · non-derivative | Direct | 36,867 |
Reported balance
After 2012-08-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2012-08-01 · Gift · Disposed 5,125 · Balance 36,867 F1: These shares are being transferred to the reporting person's Family Trust. F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 1,675 shares of common stock acquired under the Company's Employee Stock Purchase Plan. F4: These shares include 17 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Common StockSEC Table I · non-derivative | IndirectThe Nicholas A. Moore and Anna S. Richo Family Trust | 15,381 |
Reported balance
After 2012-08-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2012-08-01 · Gift · Acquired 5,125 · Balance 15,381 F1: These shares are being transferred to the reporting person's Family Trust. |
| Common StockSEC Table I · non-derivative | IndirectThe Nicholas A. Moore and Anna S. Richo Family Trust | 10,256 |
Reported balance
After 2012-08-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2012-08-01 · Sale · Disposed 5,125 · Balance 10,256 F5: The price reported is an average price. The prices ranged from $83.04 to $83.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.63 · Expires 2015-07-31 | Direct | 0 |
Reported balance
After 2012-08-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2012-08-01 · Exercise / conversion · Disposed 5,125 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 2,342.0157 |
Reported balance
Holding disclosure · report date 2012-08-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,342.0157 F6: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are being transferred to the reporting person's Family Trust.
F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 1,675 shares of common stock acquired under the Company's Employee Stock Purchase Plan.
F4: These shares include 17 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F5: The price reported is an average price. The prices ranged from $83.04 to $83.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
F6: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
EXELON CORP
Report date April 28, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2026 Directors Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-04-28 | Direct | 3,720 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 3,720 · Balance 3,720 F1: Annual restricted stock unit (RSU) award subject to the Exelon Long-term Incentive Plan (LTIP) will fully vest and be settled in shares of Exelon common stock on a 1 for 1 basis. The award will accrue additional stock units through dividend reinvestment which will vest along with the underlying award. |
| Deferred phantom share equivalentsSEC Table II · derivative / convertible security | Direct | 7,930 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,930 F2: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual restricted stock unit (RSU) award subject to the Exelon Long-term Incentive Plan (LTIP) will fully vest and be settled in shares of Exelon common stock on a 1 for 1 basis. The award will accrue additional stock units through dividend reinvestment which will vest along with the underlying award.
F2: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors.
ILLUMINA, INC.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,527 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 2,072 · Balance 8,527 F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Adamas Pharmaceuticals Inc
Report date November 24, 2021 · Filed November 24, 2021
Section 16 reporting ended · disclosed 2021-11-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 1
1 source rowRow 1 · 2021-11-24 · Other · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2030-08-28 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F6: $2.98 plus two CVRs per share underlying the stock option. F4: The shares subject to the option vest annually in equal installments over 3 years. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2021-11-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-24 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: $2.89 plus two CVRs per share underlying the stock option. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price").
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price.
F3: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value.
F4: The shares subject to the option vest annually in equal installments over 3 years.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option.
F6: $2.98 plus two CVRs per share underlying the stock option.
F7: $2.89 plus two CVRs per share underlying the stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 21:12 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,072 | $144.83 | $300,087.76 |
DisclosureSEC source: 0001110803-26-000117 · form4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,527 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| April 28, 2026 Filed Apr 29, 2026 20:06 UTC | EXELON CORP EXC · Entity 3050 | Grant2026 Directors Restricted Stock Units · Derivative | 3,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001199306-26-000006 · wk-form4_1777493158.xml · derivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,720 Underlying: Common Stock · 3,720 shares Expires 2027-04-28 F1 · derivative.exercise_price: Annual restricted stock unit (RSU) award subject to the Exelon Long-term Incentive Plan (LTIP) will fully vest and be settled in shares of Exelon common stock on a 1 for 1 basis. The award will accrue additional stock units through dividend reinvestment which will vest along with the underlying award. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 19:28 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 878 | $49.82 | $43,741.96 |
DisclosureSEC source: 0001199306-26-000004 · wk-form4_1775071735.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 11,337 F1 · balance_after: Balance includes 87 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 20:07 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 717 | $43.59 | $31,254.03 |
DisclosureSEC source: 0001199306-26-000002 · wk-form4_1767384476.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,863 Underlying: Common Stock · 717 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 65 additional phantom share equivalents accrued to the account through automatic dividend reinvestment. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 20:07 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 940 | $43.87 | $41,237.80 |
DisclosureSEC source: 0001199306-26-000002 · wk-form4_1767384476.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 10,372 F1 · balance_after: Balance includes 85 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 00:46 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 694 | $45.01 | $31,236.94 |
DisclosureSEC source: 0001199306-25-000005 · wk-form4_1759365957.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,082 Underlying: Common Stock · 694 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 55 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 00:46 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 950 | $43.43 | $41,258.50 |
DisclosureSEC source: 0001199306-25-000005 · wk-form4_1759365957.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 9,346 F1 · balance_after: Balance includes 77 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 13:39 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 719 | $43.42 | $31,218.98 |
DisclosureSEC source: 0001109357-25-000154 · wk-form4_1751463563.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,334 Underlying: Common Stock · 719 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 50 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 13:39 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 954 | $43.25 | $41,260.50 |
DisclosureSEC source: 0001109357-25-000154 · wk-form4_1751463563.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 8,320 F1 · balance_after: Balance includes 68 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| May 21, 2025 Filed May 23, 2025 21:05 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015506 · form4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,455 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. F2 · balance_after: In connection with Illumina's spin out of Grail, Inc., which was completed on June 24, 2024, all unvested equity award units were adjusted pursuant to Illumina's Amended and Restated 2015 Stock and Incentive Plan. Ms. Richo's unvested RSUs were increased by 53 units as a result of such adjustment. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:26 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 678 | $46.08 | $31,242.24 |
DisclosureSEC source: 0001109357-25-000090 · wk-form4_1743618384.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,564 Underlying: Common Stock · 678 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 44 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 18:26 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 933 | $44.19 | $41,229.27 |
DisclosureSEC source: 0001109357-25-000090 · wk-form4_1743618384.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 7,299 F1 · balance_after: Balance includes 57 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 15:38 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 830 | $37.64 | $31,241.20 |
DisclosureSEC source: 0001109357-25-000010 · wk-form4_1735918685.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,856 Underlying: Common Stock · 830 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 39 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 15:38 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 1,119 | $36.87 | $41,257.53 |
DisclosureSEC source: 0001109357-25-000010 · wk-form4_1735918685.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 6,308 F1 · ownership.direct: Balance includes 53 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:29 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 771 | $40.55 | $31,264.05 |
DisclosureSEC source: 0001109357-24-000168 · wk-form4_1727890187.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,984 Underlying: Common Stock · 771 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. F3 · balance_after: Balance includes 33 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 17:29 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 1,025 | $40.23 | $41,235.75 |
DisclosureSEC source: 0001109357-24-000168 · wk-form4_1727890187.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 5,136 F1 · balance_after: Balance includes 38 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:02 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 903 | $34.61 | $31,252.83 |
DisclosureSEC source: 0001109357-24-000142 · wk-form4_1719950532.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,188 Underlying: Common Stock · 903 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 23 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:02 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 1,161 | $35.54 | $41,261.94 |
DisclosureSEC source: 0001109357-24-000142 · wk-form4_1719950532.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 4,073 F1 · balance_after: Balance includes 31 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| May 16, 2024 Filed May 22, 2024 21:22 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016276 · form4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,622 F1 · shares: Grant of restricted stock units. 100% of the shares subject to the restricted stock unit award shall vest on the earlier of (i) the one year anniversary of the date of grant of the award and (ii) the date immediately preceding the date of the annual meeting of the company's stockholders for the year following the year of grant of the award, provided, in each case, that the awardee continues to serve as a director on such date. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 18:07 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 831 | $37.57 | $31,220.67 |
DisclosureSEC source: 0001109357-24-000090 · wk-form4_1712081219.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,259 Underlying: Common Stock · 831 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 15 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 18:07 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 1,131 | $36.48 | $41,258.88 |
DisclosureSEC source: 0001109357-24-000090 · wk-form4_1712081219.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 2,881 F1 · balance_after: Balance includes 18 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 01:50 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 870 | $35.90 | $31,233.00 |
DisclosureSEC source: 0001109357-24-000014 · wk-form4_1704246631.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,416 Underlying: Common stock · 870 shares Expires not disclosed F2 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F2 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors. F3 · balance_after: Balance includes 5 additional phantom share equivalents that were accrued to the account by the plan administrator on the ex-dividend date. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 01:50 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 1,052 | $39.21 | $41,248.92 |
DisclosureSEC source: 0001109357-24-000014 · wk-form4_1704246631.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 1,732 F1 · balance_after: Balance includes 6 additional shares acquired through automatic dividend reinvestment. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 22:36 UTC | EXELON CORP EXC · Entity 3050 | GrantDeferred phantom share equivalents · Derivative | 539 | $37.79 | $20,368.81 |
DisclosureSEC source: 0001109357-23-000081 · wk-form4_1696286163.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539 Underlying: Common stock · 539 shares Expires not disclosed F1 · derivative.exercise_price: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. F1 · derivative.exercise_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. F1 · derivative.expiration_date: Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. The stock fund is a unitized fund that consists of both Exelon common stock and short-term liquid investments. Units of the fund are acquired through quarter-end contributions and dividend reinvestment and will be settled for cash upon the termination of the reporting person's service to the board. The balance of phantom share equivalents may fluctuate due to changes in the value of the fund units. Read SEC document |
| September 30, 2023 Filed Oct 2, 2023 22:36 UTC | EXELON CORP EXC · Entity 3050 | GrantCommon stock- deferred stock units | 674 | $40.58 | $27,350.92 |
DisclosureSEC source: 0001109357-23-000081 · wk-form4_1696286163.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Exelon Corp. Directors Deferred Stock Unit Plan Disclosed balance after: 674 Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 21:08 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $5.21 | Not disclosed |
DisclosureSEC source: 0001328143-21-000088 · wf-form4_163778810423786.xml · derivative · entry 3 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F7 · price: $2.89 plus two CVRs per share underlying the stock option. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 21:08 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $5.12 | Not disclosed |
DisclosureSEC source: 0001328143-21-000088 · wf-form4_163778810423786.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-08-28 F6 · price: $2.98 plus two CVRs per share underlying the stock option. F4 · derivative.exercise_date: The shares subject to the option vest annually in equal installments over 3 years. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and with a per share exercise price less than $8.10, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, two CVRs plus the excess of (i) $8.10 over (ii) the per share exercise price of such Issuer option. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 21:08 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | OtherCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001328143-21-000088 · wf-form4_163778810423786.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 10, 2021, by and among the Issuer, Supernus Pharmaceuticals, Inc. ("Parent") and Supernus Reef, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 24, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.10 in cash plus two contingent value rights ("CVRs" and, collectively with the cash amount, the "Per Share Price"). F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, the Per Share Price. F3 · price: Disposed of pursuant to Merger Agreement in exchange for $8.10 plus two CVRs per share. The CVRs do not have a market value. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:17 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001328143-21-000061 · wf-form4_162283780916249.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-01 F2 · derivative.exercise_date: The Option shares vest in full on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:17 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001328143-21-000061 · wf-form4_162283780916249.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest on the one year anniversary of the grant date, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. Read SEC document |
| August 29, 2020 Filed Sep 1, 2020 20:44 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantStock Option (Rightto Buy) · Derivative | 20,000 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001209191-20-048935 · doc4.xml · derivative · entry 2 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-08-28 F2 · derivative.exercise_date: The shares subject to the option vest annually in equal installments over 3 years. Read SEC document |
| August 29, 2020 Filed Sep 1, 2020 20:44 UTC | Adamas Pharmaceuticals Inc ADMS · Entity 133085 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048935 · doc4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Represents the grant of restricted stock units that vest annually in equal installments over 3 years. Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 23:50 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,125 | $0.00 Strike: $62.63 | $0.00 |
DisclosureSEC source: 0001127602-12-023459 · form4.xml · derivative · entry 6 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,125 shares Expires 2015-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 23:50 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 5,125 | $83.06 | $425,697.88 |
DisclosureSEC source: 0001127602-12-023459 · form4.xml · nonDerivative · entry 4 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · The Nicholas A. Moore and Anna S. Richo Family Trust Disclosed balance after: 10,256 F5 · price: The price reported is an average price. The prices ranged from $83.04 to $83.11 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 23:50 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 5,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-023459 · form4.xml · nonDerivative · entry 3 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · The Nicholas A. Moore and Anna S. Richo Family Trust Disclosed balance after: 15,381 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 23:50 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 5,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-023459 · form4.xml · nonDerivative · entry 2 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,867 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,675 shares of common stock acquired under the Company's Employee Stock Purchase Plan. F4 · balance_after: These shares include 17 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 01, 2012 Filed Aug 1, 2012 23:50 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,125 | $62.63 | $320,978.75 |
DisclosureSEC source: 0001127602-12-023459 · form4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionIso (Right to Buy) · Derivative | 1,391 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · derivative · entry 8 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,391 shares Expires 2013-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 6,484 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · derivative · entry 7 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,484 shares Expires 2013-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 7,875 | $81.81 | $644,230.13 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · nonDerivative · entry 5 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · The Nicholas A. Moore and Anna S. Richo Family Trust Disclosed balance after: 10,256 F5 · price: The price reported is an average price. The prices ranged from $81.80 to $81.82 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · nonDerivative · entry 4 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Indirect · The Nicholas A. Moore and Anna S. Richo Family Trust Disclosed balance after: 18,131 F1 · kind: These shares are being transferred to the reporting person's Family Trust. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 7,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · nonDerivative · entry 3 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,867 F1 · kind: These shares are being transferred to the reporting person's Family Trust. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 1,675 shares of common stock acquired under the Company's Employee Stock Purchase Plan. F4 · balance_after: These shares include 17 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 1,391 | $71.88 | $99,985.08 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · nonDerivative · entry 2 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:52 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 6,484 | $71.88 | $466,069.92 |
DisclosureSEC source: 0001127602-12-023282 · form4.xml · nonDerivative · entry 1 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · derivative · entry 12 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2020-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · derivative · entry 11 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2016-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 2,950 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · derivative · entry 10 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,950 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $70.80 | $708,002.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · nonDerivative · entry 8 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,481 F3 · price: The price reported is also an average price. The prices ranged from $70.71 to $70.89 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F4 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,425 RSUs which fully vest on 4/28/2013; 2,900 RSUs which vest in two equal annual installments of 1,450 each commencing 4/26/2013; 20,000 RSUs which fully vest on 10/28/2013; 7,500 RSUs which vest in two equal installments of 2,475 each on 4/25/2013 and 4/25/2014 and one installment of 2,550 on 4/25/2015; and 3,350 RSUs which vest in three installments of 1,105, 1,106 and 1,139 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F5 · balance_after: These shares include 1,306 shares of common stock acquired under the Company's Employee Stock Purchase Plan. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 10,000 | $70.76 | $707,569.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · nonDerivative · entry 7 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,481 F2 · price: The price reported is an average price. The prices ranged from $70.73 to $70.78 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| May 01, 2012 Filed May 3, 2012 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 10,000 | $58.43 | $584,300.00 |
DisclosureSEC source: 0001127602-12-015851 · form4.xml · nonDerivative · entry 6 RICHO ANNA · CIK 0001199306 · SVP & CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.